Welcome to the Kids' Library!

The adequacy of FDA to assure the safety of the nation's drug supply hearing before the Subcommittee

United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations.
Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O., 2007. 2007

Advancing the discipline of regulatory science for medical product development : an update on progre

Washington, District of Columbia : The National Academies Press, 2016. 2016

Breakthrough business models drug development for rare and neglected diseases and individualized the

Washington, D.C. : National Academies Press, 2009. 2009

CBO's simulation model of new drug development

Adams, Christopher P., author.
Washington, D.C. : Congressional Budget Office, 2021. 2021

Committee report on license revocation & management control systems :

[Washington, D.C.] : U.S. Dept. of Justice, Drug Enforcement Administration, 1987. 1987

Committee report on scheduling of controlled substances, precursors, chemicals and controlled substa

[Washington, D.C.] : U.S. Dept. of Justice, Drug Enforcement Administration, 1987. 1987

Comparing special needs plan beneficiaries to other Medicare advantage prescription drug plan benefi

United States. Department of Health and Human Services. Office of Inspector General, author.
[Washington, D.C.] : Department of Health and Human Services, Office of Inspector General, 2008. 2008

The convergence of science and governance research, health policy, and American states

Fox, Daniel M.
Berkeley : University of California Press, c2010. 2010

Counterfeit Pharmaceutical Inter-Agency Working Group report to the Vice President of the United Sta

[Washington, D.C.] : Executive Office of the President of the United States, [2011] 2011

Deficiencies in the 340B drug discount program's database.

United States. Department of Health and Human Services. Office of Inspector General, author.
[Washington, D.C.] : Department of Health and Human Services, Office of Inspector General, 2004. 2004

Deficiencies in the oversight of the 340B drug pricing program.

United States. Department of Health and Human Services. Office of Inspector General, author.
[Washington, D.C.] : Department of Health and Human Services, Office of Inspector General, 2005. 2005

DOD pharmacy program continued efforts needed to reduce growth in spending at retail pharmacies : re

United States. Government Accountability Office.
[Washington, D.C.] : U.S. Govt. Accountability Office, [2008] 2008

Drug compounding for animals : FDA could improve oversight with better information and guidance : re

United States. Government Accountability Office, author.
Washington, DC : United States Government Accountability Office, 2015. 2015

Drug importation : the realities of safety and security : hearing before the Committee on Health, Ed

United States. Congress. Senate. Committee on Health, Education, Labor, and Pensions.
Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O., 2005. 2005

Drug importation : would the price be right? : hearing before the Committee on Health, Education, La

United States. Congress. Senate. Committee on Health, Education, Labor, and Pensions.
Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O., 2005. 2005

Drug safety an update from the Food and Drug Administration : hearing before the Subcommittee on Hea

United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health, author.
Washington : U.S. Government Printing Office, 2012. 2012

Drug shortages FDA's ability to respond should be strengthened : report to congressional requesters.

United States. Government Accountability Office.
[Washington, D.C.] : U.S. Govt. Accountability Office, [2011] 2011

Epidemic responding to America's prescription drug abuse crisis.

[Washington, D.C.] : Executive Office of the President of the United States, [Office of National Drug Control Policy], 2011. 2011

Evaluating the effectiveness of the Food and Drug Administration Modernization Act : hearing before

United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health.
Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O. [Congressional Sales Office], 2001. 2001

Examining the implications of drug importation : hearing before the Committee on the Judiciary, Unit

United States. Congress. Senate. Committee on the Judiciary.
Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O., 2008. 2008

Examining the Senate and House versions of the "Greater Access to Affordable Pharmaceuticals Act" :

United States. Congress. Senate. Committee on the Judiciary.
Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O., 2004. 2004

Experiences of health maintenance organizations with pharmacy benefit management companies.

United States. Department of Health and Human Services. Office of Inspector General, author.
[Washington, D.C.] : Department of Health and Human Services, Office of Inspector General, 1997. 1998

FDA drug approval : application review times largely reflect FDA goals : report to congressional req

United States. Government Accountability Office, author.
[Washington, D.C.] : United States Government Accountability Office, 2020. 2020

FDA warning letters : timeliness and effectiveness.

United States. Department of Health and Human Services. Office of Inspector General, author.
[Washington, D.C.] : Department of Health and Human Services, Office of Inspector General, 1999. 1999

FDA warning letters : trends and perspectives.

United States. Department of Health and Human Services. Office of Inspector General, author.
[Washington, D.C.] : Department of Health and Human Services, Office of Inspector General, 1999. 1999

FDA's drug approval process : up to the challenge? : hearing of the Committee on Health, Education,

United States. Congress. Senate. Committee on Health, Education, Labor, and Pensions.
Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O., 2005. 2005

The future of drug safety promoting and protecting the health of the public

Institute of Medicine (U.S.). Committee on the Assessment of the US Drug Safety System.
Washington, DC : National Academies Press, c2007. 2007

The Heparin disaster Chinese counterfeits and American failures : hearing before the Subcommittee on

United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations.
Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O., 2008. 2008

How Medicare plans use pharmacies, formularies, & common coverage rules.

[Washington, D.C.] : Department of Health and Human Services, Centers for Medicare & Medicaid Services, 2022. 2022

The impact of high-priced generic drugs on Medicare and Medicaid.

United States. Department of Health and Human Services. Office of Inspector General, author.
[Washington, D.C.] : Department of Health and Human Services, Office of Inspector General, 1998. 1998

Importation of prescription drugs : hearing before the Committee on Health, Education, Labor, and Pe

United States. Congress. Senate. Committee on Health, Education, Labor, and Pensions.
Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O., 2005. 2005

Lower Drug Costs Now Act of 2019 : report of the Committee on Energy and Commerce.

United States. Congress. House. Committee on Energy and Commerce, author.
[Washington, D.C.] : [U.S. Government Publishing Office], [2019]- 2019

Nonprescription drugs considerations regarding a behind-the-counter drug class : report to congressi

United States. Government Accountability Office.
[Washington, D.C.] : U.S. Govt. Accountability Office, [2009] 2009

Patents and regulatory exclusivities: issues in pharmaceutical innovation and competition

Thomas, John R., 1967- author.
[Washington, D.C.] : Congressional Research Service, [2018?]- 2018

Perspectives of drug manufacturers : abbreviated new drug applications.

United States. Department of Health and Human Services. Office of Inspector General. Office of Evaluation and Inspections, author.
[Washington, D.C.] : Department of Health and Human Services, Office of Inspector General, Office of Evaluation and Inspections, 1990. 1990

Perspectives of drug manufacturers : investigational new drug and new drug applications.

United States. Department of Health and Human Services. Office of Inspector General. Office of Evaluation and Inspections, author.
[Washington, D.C.] : Department of Health and Human Services, Office of Inspector General, Office of Evaluation and Inspections, 1990. 1990

Pharmaceutical economics and policy

Schweitzer, Stuart O.
Oxford ; New York : Oxford University Press, 2007. 2007

Pharmaceutical R&D and the evolving market for prescription drugs

Austin, David, 1960-
[Washington, D.C.] : Congressional Budget Office, [2009] 2009

Policy implications of pharmaceutical importation for U.S. consumers hearing before the Subcommittee

United States. Congress. Senate. Committee on Commerce, Science, and Transportation. Subcommittee on Interstate Commerce, Trade, and Tourism.
Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O., 2013. 2013

Prescription drug abuse : what is being done to address this new drug epidemic? : hearing before the

United States. Congress. House. Committee on Government Reform. Subcommittee on Criminal Justice, Drug Policy, and Human Resources.
Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O., 2007. 2007

Prescription drug importation

Sarata, Amanda K., author.
[Washington, D.C.] : Congressional Research Service, 2018- 2018

Prescription drug price inflation are prices rising too fast? : hearing before the Subcommittee on H

United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health.
Washington : U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O., 2012. 2012

Prescription drugs FDA's oversight of the promotion of drugs for off-label uses : report to the Rank

United States. Government Accountability Office.
[Washington, D.C.] : U.S. Govt. Accountability Office, [2008] 2008

Prescription drugs strategic framework would promote accountability and enhance efforts to enforce t

United States. Government Accountability Office.
[Washington, D.C.] : U.S. Government Accountability Office, [2005] 2005

Prescription drugs the number, role, and ownership of pharmacy services administrative organizations

United States. Government Accountability Office, author, issuing body.
Washington, D.C. : United States Government Accountability Office, 2013. 2013

Prescription for the people : an activist's guide to making medicine affordable for all

Quigley, Fran, 1962- author.
Ithaca : ILR Press, an imprint of Cornell University Press, 2017. 2017

Prescription for the people : an activist's guide to making medicine affordable for all

Quigley, Fran, 1962- author.
Ithaca : ILR Press, an imprint of Cornell University Press, 2017. 2017

Recommendation followup memorandum report : states' collection of rebates for drugs paid through med

United States. Department of Health and Human Services. Office of Inspector General, author.
Washington, DC: Department of Health and Human Services, Office of Inspector General, 2015. 2015

Regulatory exclusivity reform in the 115th Congress

Thomas, John R., 1967- author.
[Washington, D.C.] : Congressional Research Service, 2019- 2019

Replacing average wholesale price : Medicaid drug payment policy.

United States. Department of Health and Human Services. Office of Inspector General, author.
[Washington, D.C.] : Department of Health and Human Services, Office of Inspector General, 2011. 2011